Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to -$63487.0.

  • bioAffinity Technologies' Change in Accured Expenses rose 208.82% to -$63487.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $80295.0, marking a year-over-year decrease of 6917.26%. This contributed to the annual value of $248911.0 for FY2024, which is 3124.23% down from last year.
  • bioAffinity Technologies' Change in Accured Expenses amounted to -$63487.0 in Q3 2025, which was up 208.82% from -$322701.0 recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Change in Accured Expenses peaked at $506025.0 during Q4 2023, and registered a low of -$322701.0 during Q2 2025.
  • Over the past 4 years, bioAffinity Technologies' median Change in Accured Expenses value was -$25168.0 (recorded in 2022), while the average stood at $42482.2.
  • In the last 5 years, bioAffinity Technologies' Change in Accured Expenses surged by 211058.88% in 2023 and then crashed by 47622.24% in 2025.
  • Over the past 4 years, bioAffinity Technologies' Change in Accured Expenses (Quarter) stood at -$25168.0 in 2022, then soared by 2110.59% to $506025.0 in 2023, then dropped by 2.28% to $494470.0 in 2024, then plummeted by 112.84% to -$63487.0 in 2025.
  • Its last three reported values are -$63487.0 in Q3 2025, -$322701.0 for Q2 2025, and -$27987.0 during Q1 2025.